{"id":638,"date":"2026-08-23T15:56:07","date_gmt":"2026-08-23T15:56:07","guid":{"rendered":"https:\/\/syrian-biomedica.com\/?page_id=638"},"modified":"2026-08-23T15:56:07","modified_gmt":"2026-08-23T15:56:07","slug":"joseph-george-shenekji-abstract","status":"publish","type":"page","link":"https:\/\/syrian-biomedica.com\/ar\/joseph-george-shenekji-abstract\/","title":{"rendered":"Joseph George Shenekji Abstract"},"content":{"rendered":"<h1><strong>Joseph George Shenekji<\/strong><\/h1>\n<div>\n<p><strong>A Drop of Blood, a Genome, and AI: The Future of Early Cancer Detection Using Liquid Biopsy<\/strong><\/p>\n<\/div>\n<div>\n<p>Early cancer detection remains one of the most important challenges in modern medicine, as diagnosis at advanced stages is strongly associated with poorer clinical outcomes. Liquid biopsy has emerged as a promising minimally invasive approach for detecting cancer-associated molecular signals in a simple blood sample. Unlike conventional tissue biopsy, liquid biopsy can provide access to circulating tumor-derived information, including circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells, and other molecular biomarkers.<\/p>\n<\/p>\n<p>Recent advances in genomic technologies have substantially increased the ability to identify and characterize subtle molecular alterations present in blood. However, early-stage cancer detection presents a major analytical challenge because tumor-derived signals may be extremely low relative to the background of normal circulating DNA. This creates a need for highly sensitive molecular assays combined with advanced computational approaches capable of distinguishing clinically meaningful signals from biological and technical noise.<\/p>\n<\/p>\n<p>Artificial intelligence (AI) and machine learning offer a potential solution by enabling the integration and analysis of complex, high-dimensional molecular data. AI-based approaches can identify patterns across genomic alterations, DNA fragmentation profiles, methylation signatures, and other liquid-biopsy features that may not be readily detectable using conventional analytical methods. The integration of liquid biopsy, genomic profiling, and AI therefore represents a potential transition from detecting isolated biomarkers toward generating data-driven molecular signatures associated with early malignancy.<\/p>\n<\/p>\n<p>This lecture explores the emerging intersection of liquid biopsy, genomics, and artificial intelligence in early cancer detection, with particular emphasis on the journey from a small blood sample to a potential clinical decision. It discusses the biological basis of circulating biomarkers, the major technological challenges associated with low-abundance cancer signals, and the opportunities and limitations of AI-assisted interpretation. Particular attention is given to the need for analytical validation, clinical validation, standardization, interpretability, and equitable implementation before such approaches can be reliably incorporated into routine clinical practice.<\/p>\n<\/p>\n<p>The convergence of these technologies could ultimately support earlier, less invasive, and more scalable cancer detection, while also illustrating the broader transition toward data-driven precision medicine.<\/p>\n<\/div>\n<p><!--more--><br \/>\n<!-- {\"type\": \"layout\", \"children\": [{\"name\": \"Terms\", \"type\": \"section\", \"props\": {\"image_position\": \"center-center\", \"style\": \"default\", \"title_breakpoint\": \"xl\", \"title_position\": \"top-left\", \"title_rotation\": \"left\", \"vertical_align\": \"\", \"width\": \"small\"}, \"children\": [{\"type\": \"row\", \"children\": [{\"type\": \"column\", \"props\": {\"image_position\": \"center-center\", \"position_sticky_breakpoint\": \"m\", \"width_medium\": \"1-1\"}, \"children\": [{\"type\": \"headline\", \"props\": {\"content\": \"<strong>Joseph George Shenekji<\/strong>\", \"image_align\": \"left\", \"image_margin\": \"xsmall\", \"margin_top\": \"remove\", \"title_element\": \"h1\", \"title_style\": \"heading-medium\"}}, {\"type\": \"headline\", \"props\": {\"content\": \"\n\n<p><strong>A Drop of Blood, a Genome, and AI: The Future of Early Cancer Detection Using Liquid Biopsy<\/strong><\/p>\n\n\", \"image_align\": \"left\", \"image_margin\": \"xsmall\", \"margin_bottom\": \"remove\", \"title_color\": \"muted\", \"title_element\": \"div\", \"title_style\": \"h4\"}}, {\"type\": \"text\", \"props\": {\"column_breakpoint\": \"m\", \"content\": \"\n\n<p>Early cancer detection remains one of the most important challenges in modern medicine, as diagnosis at advanced stages is strongly associated with poorer clinical outcomes. Liquid biopsy has emerged as a promising minimally invasive approach for detecting cancer-associated molecular signals in a simple blood sample. Unlike conventional tissue biopsy, liquid biopsy can provide access to circulating tumor-derived information, including circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells, and other molecular biomarkers.<\/p>\n\n\\n\n\n\n\n\\n\n\n<p>Recent advances in genomic technologies have substantially increased the ability to identify and characterize subtle molecular alterations present in blood. However, early-stage cancer detection presents a major analytical challenge because tumor-derived signals may be extremely low relative to the background of normal circulating DNA. This creates a need for highly sensitive molecular assays combined with advanced computational approaches capable of distinguishing clinically meaningful signals from biological and technical noise.<\/p>\n\n\\n\n\n\n\n\\n\n\n<p>Artificial intelligence (AI) and machine learning offer a potential solution by enabling the integration and analysis of complex, high-dimensional molecular data. AI-based approaches can identify patterns across genomic alterations, DNA fragmentation profiles, methylation signatures, and other liquid-biopsy features that may not be readily detectable using conventional analytical methods. The integration of liquid biopsy, genomic profiling, and AI therefore represents a potential transition from detecting isolated biomarkers toward generating data-driven molecular signatures associated with early malignancy.<\/p>\n\n\\n\n\n\n\n\\n\n\n<p>This lecture explores the emerging intersection of liquid biopsy, genomics, and artificial intelligence in early cancer detection, with particular emphasis on the journey from a small blood sample to a potential clinical decision. It discusses the biological basis of circulating biomarkers, the major technological challenges associated with low-abundance cancer signals, and the opportunities and limitations of AI-assisted interpretation. Particular attention is given to the need for analytical validation, clinical validation, standardization, interpretability, and equitable implementation before such approaches can be reliably incorporated into routine clinical practice.<\/p>\n\n\\n\n\n\n\n\\n\n\n<p>The convergence of these technologies could ultimately support earlier, less invasive, and more scalable cancer detection, while also illustrating the broader transition toward data-driven precision medicine.<\/p>\n\n\", \"margin\": \"default\"}}]}]}]}], \"version\": \"4.5.32\"} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Joseph George Shenekji A Drop of Blood, a Genome, and AI: The Future of Early Cancer Detection Using Liquid Biopsy Early cancer detection remains one of the most important challenges in modern medicine, as diagnosis at advanced stages is strongly associated with poorer clinical outcomes. Liquid biopsy has emerged as a promising minimally invasive approach [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":"","_et_pb_custom_css":""},"class_list":["post-638","page","type-page","status-publish","hentry"],"_et_pb_custom_css":"","_links":{"self":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages\/638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/comments?post=638"}],"version-history":[{"count":0,"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/pages\/638\/revisions"}],"wp:attachment":[{"href":"https:\/\/syrian-biomedica.com\/ar\/wp-json\/wp\/v2\/media?parent=638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}